drugset / Trial / NCT03115827
Norepinephrine-targeted Therapy for Action Control in Parkinson Disease
Phase 4
Completed
15 enrolled
Vanderbilt University Medical Center
American Academy of Neurology · collabH. Lundbeck A/S · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to find out whether droxidopa, a medication that increases norepinephrine levels, may be effective in improving some aspects of cognition and movement in Parkinson's disease (PD).
Timeline
- Start
- 2017-04-18
- Primary completion
- 2018-12-21
- Completion
- 2018-12-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Droxidopa | Small molecule | 600 mg | Oral |
| Background | Carbidopa | Unknown | 200 mg | Oral |